
EP Pharma is privately owned pharmaceutical company founded by qualified pharmaceutical professionals, with decades of experience in pharma business.
EP Pharma focused on developing, manufacturing and selling generic, brand, over-the counter (OTC) and bio-similar products for patients around the globe. EP Pharma established in 2015 to represent an added value in the pharmaceutical industry in Egypt through:
* Establishing one of the best manufacturing facilities in the Middle East referenced by the international standards (GMP).
* Building a well selected and unique product portfolio in the main therapeutic areas, which ensure that community has the most efficient and up-to-date treatment that directly contributes to improving health care and quality of their life.
Based on our intensive strategy during introduction and growing stages, we made our focus on organic growth which translating our expansion plan by investing in multiple therapeutic areas such as diabetes ,gastroenterology, and cardiovascular . Recently we activated the inorganic way started with creating new channel of distribution and international partnerships , in parallel we had established and run a lot of contracts of partnerships with national and international partners.
EP Pharma is privately owned pharmaceutical company founded by qualified pharmaceutical professionals, with decades of experience in pharma business.
EP Pharma focused on developing, manufacturing and selling generic, brand, over-the counter (OTC) and bio-similar products for patients around the globe. EP Pharma established in 2015 to represent an added value in the pharmaceutical industry in Egypt through:
* Establishing one of the best manufacturing facilities in the Middle East referenced by the international standards (GMP).
* Building a well selected and unique product portfolio in the main therapeutic areas, which ensure that community has the most efficient and up-to-date treatment that directly contributes to improving health care and quality of their life.
Our medicines, and consumer healthcare products are improving quality of life for patients and consumers . But millions of people are still not getting the treatments they need because they can’t afford them, they can’t get them locally, or they simply don’t exist. Many countries continue to have under-resourced health systems. To play our part in tackling these global health challenges and extend the benefits of our products to more people, we are using open innovation to target unmet medical needs, pioneering new business models to increase access to our products and collaborating to strengthen healthcare infrastructure.
EP Pharma‘s product portfolio consists of a broad range of leading molecules for the treatment of conditions in the areas of oncology, cardiology, respiratory, neurology and gastroenterology, in addition to a fast-growing portfolio of biosimilars, brands and OTC products.